Serum PTH Associated with Malnutrition Determined by Bioelectrical Impedance Technology in Chronic Kidney Disease Patients
Table 1
Basic indicators of different CKD stage groups.
Total, n = 205
CKD1/2, n = 25
CKD3/4, n = 78
CKD5A, n = 31
CKD5B, n = 71
value
Age, yr, median (IQR)
56 (46, 67)
56 (39.5, 63)
62 (47.75, 68)
58 (46, 67)
53 (43, 64) &
0.036
Male, n (%)
127 (62%)
20 (80%)
51 (65.4%)
14 (45.2%)
42 (59.2%)
0.051
Body mass index, kg/m2, mean ± SD
24.93 ± 4.1
25.9 ± 4.53
25.82 ± 3.57
25.14 ± 3.17
23.52 ± 4.51 !,$
0.003
CKD etiology, n (%)
<0.001
Diabetic nephropathy
63 (30.7%)
9 (36%)
32 (41%)
13 (41.9%)
9 (12.7%)
Hypertensive nephropathy
28 (13.7%)
5 (20%)
11 (14.1%)
4 (12.9%)
8 (11.3%)
Glomerulonephropathy
51 (24.9%)
7 (28%)
24 (30.8%)
7 (22.9%)
13 (18.3%)
Others
22 (10.7%)
4 (16%)
7 (9%)
4 (12.9%)
7 (9.9%)
Unknown
41 (20%)
0 (0%)
4 (5.1%)
3 (9.7%)
34 (47.9%)
Parathyroid hormone, pg/ml, median (IQR)
103.5 (49.05, 452.25)
45.3 (25, 61.3)
57.25 (39.88, 94.85)
216.3 (100.5, 351.2)#,¶
773.1 (216.6, 1750.7) !,$
<0.001
Hemoglobin, g/L, mean ± SD
109.58 ± 23.06
125.12 ± 20.06
115.26 ± 21.63
93.03 ± 15.64#,¶
105.08 ± 23 !,$,&
<0.001
Albumin, g/L, median (IQR)
39.7 (34.95, 43.5)
40.2 (35.5, 45.5)
38.75 (32.95, 42.48)
38.9 (34.8, 43)
41.5 (37.9, 44)
0.056
Total cholesterol, mmol/L, median (IQR)
4.14 (3.42, 4.85)
4.74 (3.86, 5.41)
4.37 (3.75, 5.05)
4.21 (3.49, 4.83)
3.62 (3.11, 4.29) !,$
<0.001
Triglyceride, mmol/L, median (IQR)
1.69 (1.16, 2.44)
1.95 (1.26, 2.85)
1.82 (1.32, 2.82)
1.69 (1.16, 2.44)
1.49 (0.92, 2.08) $
0.036
Phosphorus, mmol/L, median (IQR)
1.35 (1.11, 1.88)
1.1 (0.95, 1.18)
1.18 (1.04, 1.36)
1.43 (1.3, 1.59)#,¶
2.11 (1.59, 2.44) !,$,&
<0.001
Calcium, mmol/L, median (IQR)
2.19 (2.09, 2.36)
2.16 (2.08, 2.26)
2.17 (2.09, 2.29)
2.12 (2, 2.17)
2.34 (2.16, 2.55) !,$,&
<0.001
IQR, interquartile range; between CKD1/2 and CKD3/4; # between CKD1/2 and CKD5A; # between CKD1/2 and CKD5A; ¶ between CKD3/4 and CKD5A; ! between CKD1/2 and CKD5B; $ between CKD3/4 and CKD5B; & between CKD5A and CKD5B.
